Misonix Announces CE Mark Approval for Nexus
August 12 2019 - 11:20AM
Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a
provider of minimally invasive therapeutic ultrasonic medical
devices that enhance clinical outcomes, announced today that it has
received Conformité Européene (CE) Mark approval for
Nexus. The CE marking confirms that Nexus meets the
requirements of the European Medical Devices Directive, which now
allows Misonix to commercialize Nexus and its disposable products
across the European Union and other CE Mark geographies.
Stavros Vizirgianakis, President and Chief
Executive Officer of Misonix stated, “We are very pleased to report
CE Mark approval for Nexus, as we continue to expand our footprint
and diversify our revenue across markets and procedures.
“Nexus marks an important leap forward for our
Company, as we are bringing to market a powerful and highly
integrated, easy-to-use system that we are confident will benefit
both healthcare providers and patients by incorporating the latest
advances in ultrasonic technology for increased efficiency and
efficacy. Given the important benefits Nexus brings to both
physicians and patients, we are confident that our ability to enter
the European market will help deliver improved outcomes for
treatments across spine surgery, neurosurgery, orthopedic surgery,
cosmetic surgery, laparoscopic surgery, and other surgical and
medical applications. In addition, the CE certification is
important to supporting continued long-term growth across our
recurring consumables revenue stream and in equipment product
sales.”
About Misonix, Inc.Misonix,
Inc. (NASDAQ: MSON) designs, manufactures and markets ultrasonic
medical devices for the precise removal of hard and soft tissue,
including bone removal, wound debridement and ultrasonic
aspiration. Misonix is focused on leveraging its proprietary
ultrasonic technology to become the standard of care in operating
rooms and clinics around the world. Misonix's proprietary
ultrasonic medical devices are used in a growing number of medical
procedures, including spine surgery, neurosurgery, orthopedic
surgery, cosmetic surgery, laparoscopic surgery, and other surgical
and medical applications. At Misonix, Better Matters to us. That is
why throughout the Company’s history, Misonix has maintained its
commitment to medical technology innovation and the development of
ultrasonic surgical products that radically improve patient
outcomes. Additional information is available on the Company's web
site at www.misonix.com.
Contact: Joe Dwyer
Joseph Jaffoni, Norberto Aja, Jennifer
NeumanChief Financial Officer
JCIRMisonix, Inc.
212-835-8500 or
mson@jcir.com631-927-9113
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Apr 2023 to Apr 2024